Age-Related Macular Degeneration Trials, Active
|
Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in Americans age 65 and older and will become increasingly more prevalent as the elderly population grows. Currently, there is no cure for the disease, only treatments to slow or stop its progression. Most of these treatments are invasive, involving laser surgery, injections or direct injection into the eye.
|
Neovista - A Phase II randomized study involving the use of an intravitreal pharmaceutical agent, alone or with Epirad90 treatment. For potential treatment of subfoveal choroidal neovascularization associated with wet macular degeneration.
|
Regeneron AMD - A Phase III study involving the use of an intravitreal pharmaceutical agent that is already FDA approved called Lucentis versus an investigational pharmaceutical agent. For the potential treatment of subfoveal choroidal neovascularization associated with wet macular degeneration.
|
| Diabetic Retinopathy Trials, Active |
Diabetes affects the body’s ability to use and store sugar properly. High blood sugar levels can damage blood vessels in the retina, as well as the nerve layer at the back of the eye that senses light and helps to send images to the brain. The damage to retinal vessels is referred to as diabetic retinopathy. There are two types of diabetic retinopathy: non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.
|
Regeneron DME - A Phase II study involving the use of an investigational intravitreal pharmaceutical agent to potentially inhibit the growth of abnormal blood vessels associated with diabetic eye disease.
|
| Vitreomacular Traction (Macular Pucker/Macular Hole) Trials, Active |
Thrombogenics - A Phase III study involving the
use of an investigational intravitreal pharmaceutical
agent to potentially release vitreal traction of macula and potentially close small macular holes. These conditions have traditionally been treated surgically.
|
| Age-Related Macular Degeneration Trials, Active But Closed to Enrollment |
Age-Related Eye Disease Study (AREDS) -
The Eye Foundation was selected by the National Eye Institute as a study site for AREDS II, a multi-center randomized trial of 4,000 participants. This Phase III study is attempting to determine whether high supplemental doses of lutein, zeaxanthin and omega-3 fatty acides affect the development of advanced AMD.
|
| Diabetic Retinopathy Trials, Active But Closed to Enrollment |
Alimera Diabetic Trials - Two Phase III trials
involving investigational intravitreal inserts of a slow release medication to potentially inhibit the growth of abnormal blood vessels associated with diabetic retinopathy.
|
Rise Trial - A Phase III trial involving the intravitreal injection of an investigational medication to potentially inhibit the growth of abnormal blood vessels associated with diabetic retinopathy.
|
* Investigators for all retinal trials: Nelson R. Sabates, MD,
Abraham Poulose, MD, Michael Cassell, MD, Komal Desai
|
